Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5393160 | 0.88 | CA1 (0.39) | MEN1KMT2AMAPTRAB9ATP53 | |
| SCHEMBL14357354 | 0.82 | LTB4R (0.38) | MEN1KMT2ANR1H2MAPTSMN1; SMN2 | |
| SCHEMBL5392988 | 0.80 | NR1H2 (0.40) | NR1H2RAB9A | |
| SCHEMBL12162029 | 0.80 | GPR119 (0.39) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12162030 | 0.74 | GPR119 (0.41) | MEN1KMT2AHTTNR1H2MAPT | |
| SCHEMBL5381807 | 0.74 | NPC1 (0.40) | RAB9A | |
| SCHEMBL6676173 | 0.73 | ALDH1A1 (0.56) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5392992 | 0.73 | NR1H2 (0.37) | NR1H2MAPT | |
| SCHEMBL5393881 | 0.73 | KMT2A (0.38) | MEN1KMT2ANR1H2RAB9A | |
| Hydrochloric Acid SCHEMBL6678335 | 0.72 | ALDH1A1 (0.54) | KMT2AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291642-B2 | Bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-06 | — | — | US | disclosed |
| US-20060100219-A1 | Novel bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100219-A1 | Novel bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BDKRB1, BDKRB2, MRGPRX1 | MEN1 354/4885KMT2A 2730/4885HTT 3739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.